Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gluconolactone is a naturally occurring polyhydroxy acid (PHA) that serves as a next-generation chemical exfoliant and humectant in dermatological applications. Chemically, it is the delta-lactone of gluconic acid. Unlike traditional alpha-hydroxy acids (AHAs) like glycolic acid, gluconolactone possesses a larger molecular structure, which limits its depth of skin penetration, thereby providing a gentler exfoliation profile with significantly reduced potential for irritation or sensory discomfort. Its mechanism of action involves the acidification of the stratum corneum and the subsequent weakening of corneodesmosomal attachments, promoting the shedding of dead keratinocytes. Additionally, gluconolactone functions as a humectant by attracting moisture to the skin and acts as a chelating agent capable of neutralizing metal ions and scavenging free radicals, which contributes to its antioxidant and photoprotective properties. It is widely utilized in the treatment of acne vulgaris, rosacea, and photoaging, and is also employed in the food industry as a sequestrant and acidifier (E575).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gluconolactone.